ADOC Adocia SA
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company's proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an ultra rapid insulin; AdOral Sema, an oral form of GLP-1 semaglutide; and AdoXLongSem, a long-lasting injectable formulation of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.…
Industry Peers
BiotechnologyKey Statistics
About Adocia (EPA: ADOC)
›
Adocia (EPA: ADOC) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 80 employees.
The shares were at 3.338 EUR on 20 November 2026, down 59.5% over 52 weeks. Its 52-week range is 2.020 EUR to 8.610 EUR: the price is 61.2% below the high and 65.2% above the low.
Its market capitalisation is 74.57M EUR.
Adocia reports an operating margin of -495.5% and revenue down 39.4% year over year.
It holds more cash than debt, a net cash position of 1.34M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 9.450 EUR is 183.1% above the current price.